Defibrillator System Research Articles

Defibrillation energy requirements and electrical heterogeneity during total body hypothermia.

Determine the effects of hypothermia on defibrillation energy requirements and cardiac electrophysiology. Prospective randomized acute intervention trial. Medical center animal laboratory. Fifteen domestic farm swine. Swine were randomized to a hypothermia group (n = 8) or a control group (n = 7). All animals were instrumented with a transvenous defibrillation system connected to a defibrillator that delivers a biphasic-truncated waveform. Values for defibrillation energy requirements were measured at baseline (normothermia, 38-40 degrees C) and during treatment with total body hypothermia (30 degrees C) or no temperature change (sham). Hypothermia was induced by circulating ice-water through anterior and posterior surgical thermal blankets. Defibrillation energy requirement values at 20%, 50%, and 80% were determined by using an up/down method. In the hypothermia group, defibrillation energy requirement values at baseline did not significantly change during hypothermia (defibrillation energy requirements 50% = 14 +/- 2 J vs. 15 +/- 2 J, respectively). Similarly, the defibrillation energy requirement values in the control group did not change from baseline to sham phase (defibrillation energy requirements 50% = 12 +/- 1 J vs. 13 +/- 1 J, respectively). Hypothermia profoundly affected cardiac electrophysiology, decreasing ventricular fibrillation threshold by 72%, conduction velocity by 25% (p < .01), and tissue excitability, while it prolonged ventricular repolarization and refractoriness by 7.5% to 15%, respectively (p < .05). Total body cooling to 30 degrees C was highly arrhythmogenic, although this unstable electrophysiological state did not alter ventricular defibrillation energy requirements. These data suggest that hypothermia may be used to slow metabolic processes without concern over the ability to successfully defibrillate and treat hypothermia-induced arrhythmias.

Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system.

Management of atrial tachyarrhythmias represents a significant challenge in patients with implantable cardioverter defibrillators (ICDs). Drug therapy of these arrhythmias is limited by moderate efficacy, ventricular proarrhythmia, and drug-device interactions. This study tested the safety and efficacy of a new dual-chamber ICD to detect and treat atrial as well as ventricular tachyarrhythmias. A dual-chamber ICD (Medtronic 7250 Jewel AF) was implanted in 293 of 303 patients at 49 centers in Europe, Canada, and North America. Specific data were collected at implant and during a mean follow-up period of 7.9+/-4.7 months. There were no clinically evident failures to detect and treat ventricular arrhythmias. In patients with at least one of the dual-chamber detection criteria activated, 1,056 of 1,192 episodes of ventricular tachycardia or fibrillation detected were judged to be appropriate (89% positive predictive accuracy). Therapy efficacy was 100% in the ventricular fibrillation zone and 98% in the ventricular tachycardia zone. Positive predictive accuracy for detection of atrial episodes was 95% (1,052/1,107). For episodes classified as atrial tachycardia by the device, the efficacy of atrial antitachycardia pacing and high-frequency (50-Hz) burst pacing was 55% and 17%, respectively. High-frequency burst pacing terminated 16.8% of episodes classified as atrial fibrillation, and atrial defibrillation had an estimated efficacy of 76%. The actuarial estimates of 6-month complication-free survival and total survival were 88% and 94%, respectively. This novel dual-chamber ICD is capable of safely and effectively discriminating atrial from ventricular tachyarrhythmias and of treating atrial tachyarrhythmias without compromising detection and treatment of ventricular tachyarrhythmias.

Animal study on surface‐modified defibrillator systems: Indications for enhanced infection resistance

One of the most important problems with ICD systems is infection. The aim of this study was an in vivo evaluation of the efficacy of defibrillator systems in terms of infection resistance. The polyurethane leads were coupled with heparin and loaded with the antibiotic gentamicin, while the PGs were modified to release gentamicin. Group I was comprised of 10 pigs implanted with either a standard or a modified system for 2 weeks; group II was implanted during 4 weeks. The lead was inserted into the heart wall via the jugular vein. The other end was subcutaneously tunneled to the armpit where the PG was positioned. A cocktail of Staphylococcus aureus and epidermidis was injected at the site of the PG. Evaluation was performed macroscopically, by taking bacterial swabs during explantation and by microscopic processing. The results showed that 3 out of 5 modified defibrillator-systems in group I and 1-2 out of 5 in group II were judged as noninfected, whereas all standard systems were infected. Infection rates of the remaining modified defibrillators showed variances, as found with the standards, from slight to moderate to high, to even high/severe in group II (1x standard and 1x modified). With the modified systems, this may be related to production of humoral factors by an intensified early tissue reaction, as indicated by a swelling at day 6 at the site of the PG. When infected, whether or not modified, usually only Staphylococcus aureus was present. Spreading of infection seemed to occur by inoculation via blood, for example, based on the observation that group II in general showed an increase in infected fibrotic overgrowth in the heart, while infectious problems were low in the jugular vein. It is concluded that the modification at short term shows enhanced infection resistance. An increased infection rate already at 4 weeks, however, indicates that the modification may not hold in the long run. Special attention is needed concerning the more intense early tissue reaction.

Animal study on surface‐modified defibrillator systems: Indications for enhanced infection resistance

Animal study on surface‐modified defibrillator systems: Indications for enhanced infection resistance

Implantable dual-chamber cardioverter-defibrillator-pacemaker

The fifth generation of implantable cardioverter-defibrillators offer enhanced modes of detection of atrial and ventricular arrhythmias, antitachycardia pacing and shocks, multiprogrammability, intracardiac electrogram storage, and all functions of antibradycardia dual-chamber pacing including rate responsiveness and mode switching. There is no consensus on the indications for dual-chamber pacemaker defibrillator systems. This review focuses on the four major options of newer devices that might benefit patients: 1) permanent dual-chamber pacing in ischemic coronary disease patients, 2) detection and management of atrial fibrillation or other atrial tachyarrhythmias, 3) some newer indications for pacing, and 4) the suppression of inappropriate interventions. On the basis of published data, newer indications for the dual-chamber systems, advantages and limitations, and future perspectives are discussed.

Effect of sensing system on the incidence of myopotential oversensing during bradycardia pacing in implantable cardioverter-defibrillators

Oversensing during bradycardia pacing, sometimes leading to spurious tachyarrhythmia detection and inappropriately delivered shocks, has been reported with Ventritex (St. Jude Corporation, Sunnyvale, California) Cadence (models V-100 and V-110) implantable cardioverter-defibrillators (ICDs). 1 Kelly P.A. Mann D.E. Damle R.S. Reiter M.J. Oversensing during ventricular pacing in patients with a third-generation implantable cardioverter-defibrillator. J Am Coll Cardiol. 1994; 23: 1531-1534 Abstract Full Text PDF PubMed Scopus (47) Google Scholar , 2 Rosenthal M.E. Paskman C. Noise detection during bradycardia pacing with a hybrid nonthoracotomy implantable cardioverter defibrillator system. PACE. 1998; 21: 1380-1386 Crossref Scopus (9) Google Scholar , 3 Peters W. Kowallik P. Wittenberg G. Scholl C. Meesmann M. Inappropriate discharge of an implantable cardioverter defibrillator during atrial flutter and intermittent ventricular antibradycardia pacing. J Cardiovasc Electrophysiol. 1997; 8: 1167-1174 Crossref PubMed Scopus (15) Google Scholar One cause of this problem is sensing of diaphragmatic or abdominal myopotentials in the setting of the high sensitivity that automatically occurs during bradycardia pacing. 2 Rosenthal M.E. Paskman C. Noise detection during bradycardia pacing with a hybrid nonthoracotomy implantable cardioverter defibrillator system. PACE. 1998; 21: 1380-1386 Crossref Scopus (9) Google Scholar Ventritex ICDs use a stepwise automatic amplifier gain control, and amplifier gain is continuously maximal during bradycardia pacing, with a minimal sensed signal of approximately 0.2 mV. 4 Reiter M.J. Mann D.E. Sensing and tachyarrhythmia detection problems in implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 1996; 7: 542-558 Crossref PubMed Scopus (60) Google Scholar Newer Ventritex devices, Cadet, Contour, and Angstrom (models V-115, V-145, V-180, and V-190) use a similar automatic gain control, although gain changes occur more rapidly than in the Cadence models. 5 Mann D.E. Damle R.S. Kelly P.A. Landers M. Otto L. Reiter M.J. Comparison of oversensing during bradycardia pacing in two types of implantable cardioverter-defibrillator systems. Am Heart J. 1998; 136: 658-663 Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar Other ICDs use different sensing algorithms. Medtronic (Minneapolis, Minnesota) and CPI Guidant (St. Paul, Minnesota) devices automatically adjust sensitivity or gain on a beat-by-beat basis. Sensitivity or gain is adjusted according to the amplitude of each sensed complex. Between complexes, sensitivity or gain exponentially increases, eventually reaching a maximum level that in some devices is programmable. In Medtronic and CPI devices, sensitivity or gain during bradycardia pacing is maximal for less of the cardiac cycle than in Ventritex devices, and thus the propensity to oversense could be less in these devices. 4 Reiter M.J. Mann D.E. Sensing and tachyarrhythmia detection problems in implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 1996; 7: 542-558 Crossref PubMed Scopus (60) Google Scholar To assess the effect these differences in sensing function may have on oversensing of myopotentials, we performed the following prospective study.

The Value of Predischarge ICD Tests in Patients with a Successful Peroperative Test

An internal cardioverter defibrillator (ICD) is normally extensively tested during implantation. The necessity of retesting prior to discharge of the patient is a matter of debate. In our material of 30 patients undergoing first-time implantation of a transvenous internal defibrillator system, we retrospectively compare the predischarge defibrillation test with the peroperative test. A successful peroperative defibrillation test with no failed shocks at 10 J below maximal energy level was followed by a successful predischarge test with the same safety margin in 18/19 patients, while one patient required a maximal energy ICD shock for conversion at the predischarge test. We conclude that the predischarge defibrillation test can be omitted if the peroperative test was successful, with no failed shocks at 10 J below maximal energy level and if the shock therapy is set to maximal energy level.

Atrial defibrillation with a transvenous lead: A randomized comparison of active can shocking pathways

OBJECTIVESThe purpose of this study was to compare transvenous atrial defibrillation thresholds with lead configurations consisting of an active left pectoral electrode and either single or dual transvenous coils.BACKGROUNDLow atrial defibrillation thresholds are achieved using complex lead systems including coils in the coronary sinus. However, the efficacy of more simple ventricular defibrillation leads with active pectoral pulse generators to defibrillate atrial fibrillation (AF) is unknown.METHODSThis study was a prospective, randomized assessment of shock configuration on atrial defibrillation thresholds in 32 patients. The lead system was a dual coil Endotak DSP lead with a left pectoral pulse generator emulator. Shocks were delivered either between the right ventricular coil and an active can in common with the proximal atrial coil (triad) or between the atrial coil and active can (transatrial).RESULTSDelivered energy at defibrillation threshold was 7.1 ± 6.0 J in the transatrial configuration and 4.0 ± 4.2 J in the triad configuration (p < 0.005). Moreover, a low threshold (≤3 J) was observed in 69% of subjects in the triad configuration but only 47% in the transatrial configuration. Peak voltage and shock impedance were also lowered significantly in the triad configuration. Left atrial size was the only clinical predictor of the defibrillation theshold (r = 0.57, p < 0.002).CONCLUSIONSThese results indicate that low atrial defibrillation thresholds can be achieved using a single-pass transvenous ventricular defibrillation lead with a conventional ventricular defibrillation pathway. These data support the development of the combined atrial and ventricular defibrillator system.

Energy steering of biphasic waveforms using a transvenous three electrode system.

The optimal electrode configuration for endocardial defibrillation is still a matter of debate. Current data suggests that a two pathway configuration using the right ventricle (RV) as cathode and a common anode constituted by a superior vena cava (SVC) and a pectoral can (C) is the most effective combination. This may be related to the more uniform voltage gradient created by shocks delivered using this configuration. We hypothesized that more effective waveforms could be obtained by varying the distribution of the shock current between the two pathways of a three electrode endocardial defibrillation system. In 12 pigs, we compared the characteristics and the defibrillation efficacy of six biphasic waveforms discharged using either a two (RV-->C) or a three (RV-->SVC + C) electrode combination with the following configurations: Configuration 1 (W1): the RV apical coil was used as a cathode and the subcutaneous C as anode (RV-->C). Configuration 2 (W2): The RV was used as cathode and the combination of the atriocaval coil (SVC) and the subcutaneous C as anode (RV-->SVC + C). Configuration 3 (W3): The RV-->C was used for the first 25% of f+ and RV-->SVC + C for the remainder of the discharge including f 2 Configuration 4 (W4): The RV-->C was used for the first 50% of f+ and RV-->SVC + C for the remainder of the discharge including f 2 Configuration 5 (W5): The RV-->C was used for the first 75% of f+ and RV-->SVC + C for the remainder of the discharge including f 2. Configuration 6 (W6): The RV-->C was used for f+ and RV-->SVC + C for f 2. As an increasing fraction of the waveform was discharged using the RV-->SVC + C pathways, the impedance and the pulse width decreased while the tilt, the peak, and the average current significantly increased. The waveforms delivered using the RV-->SVC + C configuration for 100% or 75% of their duration had significantly lower stored energy DFT than the other waveform. Current distribution between three endocardial electrodes can be altered during the shock and generates waveforms with different characteristics. Shocks with 75% or more of the current flowing to the RV-->SVC + C required the lowest stored energy to defibrillate. This method of energy steering could be used to optimize current delivery in a three electrodes system.

Biventricular pacing in patients with congestive heart failure: two prospective randomized trials

Epidemiologic studies suggest that 20–30% of patients diagnosed with symptomatic congestive heart failure (CHF) have intraventricular conduction disorders characterized by a discoordinate contraction pattern and wide QRS. Biventricular pacing is an emerging therapy allowing simultaneous electrical stimulation of the right and left ventricles with the use of an implantable pacing system. The aim of this article is to describe 2 prospective randomized multicenter trials examining the effects of biventricular pacing on functional capacity, quality of life, and hemodynamic status in patients with dilated cardiomyopathy and intraventricular delay. The VIGOR CHF Trial is designed to assess functional and symptomatic improvement in heart failure patients with biventricular pacing and without a concomitant indication for conventional bradycardia pacemaker therapy. To assess for potential placebo effects, patients are randomized to receive either biventricular pacemaker therapy or no pacing therapy for the first 6 weeks, after which both groups receive pacing therapy. The VENTAK CHF trial uses an implantable cardioverter defibrillator system (ICD) designed to provide chronic biventricular pacing therapy in addition to treating ventricular tachyarrhythmias. All patients receive conventional ICD and CHF therapy throughout the study and are randomized in a 2-period crossover design to receive either no pacing or biventricular pacing for 3-month intervals. Patient enrollment in both studies is ongoing, with a closed analysis. The unique designs of these trials provide the opportunity to study this therapy in high-risk patients who have been optimally treated for heart failure.

A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach

The implantable cardioverter defibrillator (ICD), a primary therapeutic option for preventing sudden cardiac death, has rapidly evolved since being introduced clinically in 1980. Technologic advances in several key areas have enabled ICDs to provide more sophisticated rhythm management. Recent emphasis has been placed on dual-chamber ICDs possessing adaptive-rate pacing capabilities. Adoption of dual-chamber ICD systems has been rapid. The capabilities of future ICD systems will be governed by an integrative strategy that brings together sets of features specifically targeted at multifaceted rhythm disorders. The addition of atrial therapy will require more sophisticated rhythm discrimination algorithms. ICD technology will improve on several fronts including leads, integrated circuits, batteries, and capacitors. Additionally, state-of-the-art pacemaker technology will continue to be incorporated into ICDs. As these new ICD systems become increasingly sophisticated from an engineering viewpoint, tremendous emphasis will be placed on decreasing the complexity of programming, device interrogation, and patient monitoring during routine patient follow-up. Vast improvements in ICD programming systems may ultimately permit the 1-minute follow-up.

Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.

We sought to investigate the nature of terminal events and potential contributory clinical and nonclinical (e.g., device-related) factors associated with sudden death (SD) in recipients of an implantable cardioverter-defibrillator (ICD). The ICD is very effective in terminating ventricular tachycardia (VT) or ventricular fibrillation (VF), but protection against SD is not absolute. Little is known about the nature and potential causes of SD in patients with ICDs. We analyzed 25 cases of out-of-hospital SD among patients enrolled in the clinical investigation of the Cadence Tiered-Therapy Defibrillator System. All patients (24 men and 1 woman, mean age 62+/-10 years) received epicardial lead systems. The majority (92%) had coronary artery disease and a previous myocardial infarction (MI), with a mean left ventricular ejection fraction 0.25+/-0.07. At device implantation, the mean defibrillation threshold was 13+/-5 J. Sudden death occurred 13+/-11 months later. Twenty patients (80%) had received appropriate ICD therapies before death, and 18 (72%) were receiving > or = 1 antiarrhythmic drugs at the time of death. Sudden death was tachyarrhythmia-associated in 16 patients (64%), non-tachyarrhythmia-associated in 7 (28%) and indeterminate in 2 (8%). In the 16 patients with tachyarrhythmia-associated SD, the overall first therapy success rate in tachycardia and fibrillation zones was 60% and 67%, respectively. However, despite protracted therapies (> or = 2 shocks) in 7 (66%) of 12 patients who received fibrillation therapies, the final tachyarrhythmic episode was ultimately terminated by the ICD in 15 (94%) of the 16 patients, whereas 1 patient died after multiple (initially successful) internal and external shocks for intractable VT/VF during exercise. In 10 patients (40%) one or more, primarily clinical, factors potentially contributory to SD were identified: heart failure (n=8), angina (n=2), hypokalemia (n=1), adverse antiarrhythmic drug treatment (n=1) and acute MI (n=1). An additional 10 patients (40%) had experienced an increase in frequency of ICD shocks within 3 months of SD. Appropriate battery voltages and normal circuitry function were found in all devices interrogated and analyzed after death. In this select group of patients receiving a third-generation ICD, SD was associated with VT or VF events in nearly two-thirds of patients, and death occurred despite ultimately successful, although often protracted, device therapies. These observations, along with evidence of recent worsening clinical status, suggest acute cardiac mechanical dysfunction as a frequent terminal factor. In recipients with ICDs, SD directly attributable to device failure seems to be rare.

Influence of Anisotropy on Local and Global Measures of Potential Gradient in Computer Models of Defibrillation

A heart-torso model including fiber orientation is used to calculate electric field strength in an active-can transvenous defibrillation system and estimate errors due to inadequate description of the anisotropy of the myocardium. Using a minimum potential gradient (5 V/cm) in a critical mass (95%) of the tissue, the estimated defibrillation voltage threshold for a right ventricular transvenous lead placement differs by only 4.5% when using isotropic myocardial conductivity compared to a model with realistic fiber architecture. In addition, pointwise comparisons of the two solutions reveal differences of 10.8% rms in potential gradient strength and 31.6% rms in current density magnitude in the myocardium, resulting in a change in the location of the low gradient regions. These results suggest that if a minimum potential gradient throughout the heart is necessary to avoid reinitiation of fibrillatory wave fronts, then isotropic models are adequate for modeling the electric field in the heart. Alternatively, the model demonstrates the use of physiologically based descriptions of anisotropy and fiber orientation, which will soon allow simulations of shock induced membrane polarization during defibrillation.

Influence of polarity reversal on defibrillation success with biphasic shocks and a transvenous/subcutaneous defibrillator system in a porcine animal model.

Clinical studies show that polarity reversal affects defibrillation success in transvenous monophasic defibrillators. Current devices use biphasic shocks for defibrillation. We investigated in a porcine animal model whether polarity reversal influences defibrillation success with biphasic shocks. In nine anesthetized, ventilated pigs, the defibrillation efficacy of biphasic shocks (14.3 ms and 10.8 ms pulse duration) with "initial polarity" (IP, distal electrode = cathode) and "reversed polarity" (RP, distal electrode = anode) delivered via a transvenous/subcutaneous lead system was compared. Voltage and current of each defibrillating pulse were recorded on an oscilloscope and impedance calculated as voltage divided by current. Cumulative defibrillation success was significantly higher for RP than for IP for both pulse durations (55% vs 44%, P = 0.019) for 14.3 ms (57% vs 45%, P < 0.05) and insignificantly higher for 10.8 ms (52% vs 42%, P = ns). Impedance was significantly lower with RP at the trailing edge of pulse 1 (IP: 44 +/- 8.4 vs RP: 37 +/- 9.3 with 14.3 ms, P < 0.001 and IP: 44 +/- 6.2 vs RP: 41 +/- 7.6 omega with 10.8 ms, P < 0.001) and the leading edge of pulse 2 (IP: 37 +/- 5 vs RP: 35 +/- 4.2 omega with 14.3 ms, P = 0.05 and IP: 37.5 +/- 3.7 vs RP: 36 +/- 5 omega with 10.8 ms, P = 0.02). In conclusion, in this animal model, internal defibrillation using the distal coil as anode results in higher defibrillation efficacy than using the distal coil as cathode. Calculated impedances show different courses throughout the shock pulses suggesting differences in current flow during the shock.

Spontaneous reinitiation of atrial fibrillation following transvenous atrial defibrillation.

Spontaneous reinitiation of atrial fibrillation (AF) has not been systematically looked at in patients undergoing transvenous AF. This study involved 11 patients, the mean age 60 +/- 8 years, 3 male and 8 female, in whom transvenous atrial defibrillation successfully converted AF to sinus rhythm. Eight patients had paroxysmal AF and three patients had chronic persistent AF for 4 weeks or more. Four patients were taking antiarrhythmic medications at the time of testing. Multipolar transvenous catheters were positioned inside the coronary sinus, right atrium, and the right ventricle. Atrial defibrillation testing was performed using the METRIX atrial defibrillation system in nine patients and the Ventritex HVSO2 in the remaining two patients. A total of 64 therapeutic shocks (range 3-11) were delivered in the 11 patients, and 31 of these successfully converted AF to sinus rhythm. In four patients spontaneous AF was reinitiated following 12 successful transvenous atrial defibrillation episodes. The mean time to reinitiation of AF following shock delivery and restoration of sinus rhythm was 8.26 +/- 5.25 seconds, range 1.8-19.9 seconds. All 12 episodes of spontaneous AF were preceded by a spontaneous premature atrial complex. The coupling interval of the premature atrial complexes was 443 +/- 43 ms, range 390-510 ms. None of the patients taking antiarrhythmic medications or those demonstrating no premature atrial complexes had spontaneous reinitiation of AF. In conclusion, spontaneous reinitiation of AF can occur in a significant proportion of patients with AF undergoing transvenous atrial defibrillation. This phenomenon is preceded by the occurrence of atrial premature complex. Findings of this study may have significant clinical implications.

Simplified Implantation of Single-Lead Pectoral Cardioverter Defibrillators Using Device-Based Testing

Device-based testing of single-lead pectoral defibrillators (defibrillation efficacy testing without an external defibrillation system after complete implantation of the device) resulted in an adequate defibrillation threshold (< or = 20 J) in 45 of 50 study patients (90%). Mean surgical implantation time (skin to skin) was 62 +/- 29 minutes without perioperative mortality and without implantable cardioverter defibrillator infection during follow-up. Thus, device-based testing appears to be a simple and safe method to test defibrillation efficacy of single-lead pectoral defibrillators.

Lead failure caused by twiddler's syndrome in subpectorally implanted unipolar single-lead cardioverter-defibrillators

Twiddler's syndrome, first described in 1968 by Bayless, Beanlands, and Baird 1 as a rare complication in patients with pacemakers, is characterized by dislodgment of transvenous leads by the twisting of pulse generators in the subcutaneous pocket, resulting in lead malfunction. As might be expected, similar complications could arise in the case of subpectorally placed implantable cardioverterdefibrillators (ICDs). Especially in unipolar defibrillation systems, which use the housing of the ICD itself as the second active defibrillation electrode, device migration could have a fatal influence on the defibrillation field. We report two cases of this rare complication. PATIENT 1. A 66-year-old male patient (body index 24.5 kg/m 2) with severe coronary artery disease and ventricular tachycardia was referred to our clinic. Bypass surgery was

Right side implant of the unipolar single lead defibrillation system.

The active can defibrillator has been designed for implantation in the left prepectoral region. Whether this system can be successfully implanted on the right side is unknown. We describe six cases in which placement of the unipolar single lead defibrillation system was successfully attempted in the right prepectoral region due to impediments on the left side. The mean age of the patients was 62 +/- 12 years. Five patients had ischemic heart disease and one idiopathic dilated cardiomyopathy. The endocardial defibrillation electrode was placed in the right ventricle through the right subclavian vein and positioned at the apex in two patients and in the septal position in four patients. Defibrillation threshold testing was performed using a step-up/step-down protocol beginning at 12 J with 3-J increments or decrements. Defibrillation threshold was defined as the lowest energy of the first shock able to terminate ventricular fibrillation. The generator models used were the Medtronic 7218C in 1 patient, the Medtronic 7219C in 3 patients, and the Ventritex Cadet 115 AC in 2 patients. The mean defibrillation threshold was 15 +/- 3 J. The defibrillation thresholds were retested at 1, 3, and 6 months, and showed no significant change in five patients but decreased from 15 J to 12 J in one patient. The presence of impediments on the left side should not preclude attempts to place the unipolar active can system in the right prepectoral region.

Combined use of non-thoracotomy cardioverter defibrillators and endocardial pacemakers.

OBJECTIVE: To study the potential interactions in patients with endocardial permanent pacemakers and non-thoracotomy implantable cardioverter defibrillator (ICD) systems. DESIGN: Case series and cohort study. SETTING: Tertiary referral centre. PATIENTS:...

ICD-antiarrhythmic drug and ICD-pacemaker interactions.

Antiarrhythmic drugs and separate bradycardia pacing systems are prescribed commonly in patients with implantable cardioverter defibrillators (ICDs). Adverse effects of antiarrhythmic drugs on ICD function and adverse interactions between ICDs and pacemakers have been documented. The effect of antiarrhythmic drugs on the defibrillation threshold (DFT) in patients has not been well assessed. Most studies have been performed in animal models in which cardiac function was normal and drug doses were supraphysiologic. In addition, most studies have utilized monophasic defibrillation shock waveforms and epicardial lead systems. Despite the lack of clinical data applicable to current defibrillation systems, it appears that chronic amiodarone administration causes a significant DFT increase. In addition, antiarrhythmic drugs can influence antitachycardia pacing and tachycardia sensing. Defibrillation shocks can cause transient failure of pacemaker sensing and pacing, and cause spurious pacemaker reprogramming. Pacemaker function can result in ICD oversensing, leading to inappropriate therapy, or cause ICD undersensing, potentially resulting in failure to deliver therapy during ventricular fibrillation. The susceptibility of an ICD to undersensing appears related to the amplitude of the pacing stimulus artifact recorded by the ICD rate-sensing circuit and to the characteristics of the fibrillation electrogram. Preliminary data suggest that undersensing of ventricular fibrillation by current ICDs is an unlikely event.